William Blair Upgrades Larimar Therapeutics (LRMR) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
- HubSpot to cut 7% of workforce in restructuring plan
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Caribou Biosciences to halt CAR-T programs, explore sale
- Stryker names Spencer Stiles as CEO, Lobo moves to chair
- Francis Halzen wins Nobel physics prize for Antarctic 'ghost particle' hunt
Larimar Therapeutics (LRMR) CEO and CFO Buy Stock in Recent Offering
September 19, 2022 8:10 AM EDTLarimar Therapeutics (NASDAQ: LRMR) sees a couple of insider buys. Shares were purchased in the underwritten offering of Larimar Therapeutics, Inc. at the offering price, which closed on September 16, 2022.
CEO, Carole Ben-Maimon, bought 31,746 shares on 09/16/22 at $3.15CFO, Michael Celano, bought 31,746 shares on 09/16/22 at $3.15... More


